Radiation treatment planning firm CMS of St. Louis has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Monaco, its next-generation intensity-modulated radiation therapy (IMRT) planning platform.
Monaco, which was developed in collaboration with the University of Tübingen in Germany, features biological cost functions with multicriterial constrained optimization, a leaf sequencer, and Monte Carlo dose calculation algorithm. Monaco also is fully integrated with CMS' Focal platform, providing connectivity and integration with Focal's advanced fusion, contouring, simulation, and plan review capabilities.
CMS previously announced the release of Monaco 1.0 in July and the first clinical implementations have been completed in Europe and Australia.
By AuntMinnie.com staff writers
October 16, 2007
Related Reading
CMS unveils deals, FDA submission, July 23 2007
CMS, Toshiba collaborate on Idaho installation, June 22, 2007
CMS wins installation in Bahamas, May 2, 2007
Toshiba, CMS ink deal, August 8, 2006
Copyright © 2007 AuntMinnie.com
